PMID- 21098326
OWN - NLM
STAT- MEDLINE
DCOM- 20110215
LR  - 20151119
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 29
IP  - 1
DP  - 2011 Jan 1
TI  - Disease course patterns after discontinuation of bevacizumab: pooled analysis of 
      randomized phase III trials.
PG  - 83-8
LID - 10.1200/JCO.2010.30.2794 [doi]
AB  - PURPOSE: Preclinical studies have suggested accelerated tumor growth, local 
      invasion, and distant metastasis after withdrawal of treatment with some 
      antiangiogenic agents. To investigate whether discontinuation of bevacizumab 
      treatment is associated with accelerated disease progression or increased 
      mortality, we retrospectively analyzed five randomized, placebo-controlled phase 
      III studies in 4,205 patients with breast, colorectal, renal, and pancreatic 
      cancer. METHODS: Time from treatment discontinuation to progressive disease or 
      death was analyzed in patients discontinuing bevacizumab/placebo as a result of 
      adverse events (AEs). Mortality rates were assessed at 30, 60, 90, 120, 150, 180, 
      and 210 days after the last bevacizumab/placebo dose in the following two groups: 
      patients discontinuing bevacizumab/placebo as a result of AEs and patients 
      discontinuing bevacizumab/placebo for any reason. In the same groups, time from 
      treatment discontinuation to death was analyzed. Data on disease progression 
      pattern were available and analyzed in four of the five studies. RESULTS: In the 
      pooled analysis, median time from discontinuation as a result of AEs to 
      progression/death was 3.0 months (95% CI, 2.6 to 3.8 months) for placebo and 4.0 
      months (95% CI, 3.4 to 4.6 months) for bevacizumab (hazard ratio, 0.93; 95% CI, 
      0.79 to 1.10). Mortality rates from 30 days to 210 days after treatment 
      discontinuation and time from discontinuation to death were similar in 
      bevacizumab- and placebo-treated patients. In addition, similar patterns of 
      disease progression were seen in bevacizumab- and placebo-treated patients. 
      CONCLUSION: This retrospective analysis of five placebo-controlled clinical 
      trials does not support a decreased time to disease progression, increased 
      mortality, or altered disease progression pattern after cessation of bevacizumab 
      therapy.
FAU - Miles, David
AU  - Miles D
AD  - Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, London HA6 2RN, United 
      Kingdom. david.miles@doctors.org.uk
FAU - Harbeck, Nadia
AU  - Harbeck N
FAU - Escudier, Bernard
AU  - Escudier B
FAU - Hurwitz, Herbert
AU  - Hurwitz H
FAU - Saltz, Leonard
AU  - Saltz L
FAU - Van Cutsem, Eric
AU  - Van Cutsem E
FAU - Cassidy, Jim
AU  - Cassidy J
FAU - Mueller, Barbara
AU  - Mueller B
FAU - Sirzen, Florin
AU  - Sirzen F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101122
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
CIN - J Clin Oncol. 2011 May 1;29(13):e384-5; author reply e386. PMID: 21422432
MH  - Antibodies, Monoclonal/*administration & dosage/*adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Clinical Trials, Phase III as Topic
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
EDAT- 2010/11/26 06:00
MHDA- 2011/02/16 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/02/16 06:00 [medline]
AID - JCO.2010.30.2794 [pii]
AID - 10.1200/JCO.2010.30.2794 [doi]
PST - ppublish
SO  - J Clin Oncol. 2011 Jan 1;29(1):83-8. doi: 10.1200/JCO.2010.30.2794. Epub 2010 Nov 
      22.